Furthermore, our results suggest that paricalcitol could be a potential therapeutic option in the treatment of renal fibrosis by targeting the pericyte biology in hypoxia-induced and TGF-β1-induced injury. The gene discussed is TGFB1; the disease is renal fibrosis.